 |
|
|
| |
COMPARABILITY OF 48-WEEK EFFICACY AND SAFETY OF CABOTEGRAVIR
AND RILPIVIRINE LONG-ACTING EVERY 8 WEEKS TO STANDARD OF CARE
IN SUPPRESSED PEOPLE LIVING WITH HIV-1
|
| |
| |
Glasgow 2020 Oct 5-8 virtual
Reported by Jules Levin
Vasiliki Chounta,1 Sonya Snedecor,2 Sterling Wu,3 Nicolas Van de Velde1
1ViiV Healthcare, Brentford, UK; 2Pharmerit International, Bethesda, MD, USA; 3GlaxoSmithKline, Collegeville, PA, USA
|
| |
|
|
|
|
|
